Susan D'COsta

Susan D'COsta

Auto-generated profile, based on publicly available information

Susan D'COsta

Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Genetics
Verified
Journal Article
Closed access
PDF file
ETEliza Thulson
Eliza Thulson
EDEric S Davis
Eric S Davis
SDSusan D’cOsta
Susan D’cOsta
PCPhilip R Coryell
Philip R Coryell
NKNicole E Kramer
Nicole E Kramer
DPDouglas Phanstiel
Douglas Phanstiel
Genome-wide association studies have identified over 100 loci associated with osteoarthritis risk, but the majority of osteoarthritis risk variants are noncoding, making it difficult to identify the impacted genes for further study and therapeutic development. To address this need, we used a multiomic approach and genome editing to identify and functionally characterize potential osteoarthritis risk genes. Computational analysis of genome-wide association studies and ChIP-seq data revealed that chondrocyte regulatory loci are enriched for osteoarthritis risk variants. We constructed a chondrocyte-specific regulatory network by mapping 3D chromatin structure and active enhancers in human chondrocytes. We then intersected these data with our previously collected RNA-seq dataset of chondrocytes responding to fibronectin fragment, a known osteoarthritis trigger. Integration of the 3 genomic datasets with recently reported osteoarthritis genome-wide association study variants revealed a refined set of putative causal osteoarthritis variants and their potential target genes. One of the putative target genes identified was SOCS2, which was connected to a putative causal variant by a 170-kb loop and is differentially regulated in response to fibronectin fragment. CRISPR-Cas9-mediated deletion of SOCS2 in primary human chondrocytes from 3 independent donors led to heightened expression of inflammatory markers after fibronectin fragment treatment. These data suggest that SOCS2 plays a role in resolving inflammation in response to cartilage matrix damage and provides a possible mechanistic explanation for its influence on osteoarthritis risk. In total, we identified 56 unique putative osteoarthritis risk genes for further research and potential therapeutic development.

16 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MBMarielle L. Bond
Marielle L. Bond
IQIvana Y. Quiroga-Barber
Ivana Y. Quiroga-Barber
SDSusan D’costa
Susan D’costa
YWYijia Wu
Yijia Wu
JBJessica L. Bell
Jessica L. Bell
Hyejung WonHyejung Won
Hyejung Won
Genome-wide association studies have identified loci associated with Alzheimer’s Disease (AD), but identifying the exact causal variants and genes at each locus is challenging due to linkage disequilibrium and their largely non-coding nature. To address this, we performed a massively parallel reporter assay of 3,576 AD-associated variants in THP-1 macrophages in both resting and proinflammatory states and identified 47 expression-modulating variants (emVars). To understand the endogenous chromatin context of emVars, we built an activity-by-contact model using epigenomic maps of macrophage inflammation and inferred condition-specific enhancer-promoter pairs. Intersection of emVars with enhancer-promoter pairs and microglia expression quantitative trait loci allowed us to connect 39 emVars to 76 putative AD risk genes enriched for AD-associated molecular signatures. Overall, systematic characterization of AD-associated variants enhances our understanding of the regulatory mechanisms underlying AD pathogenesis.

5 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NKNicole E Kramer
Nicole E Kramer
PCPhilip Coryell
Philip Coryell
SDSusan D'Costa
Susan D'Costa
ETEliza Thulson
Eliza Thulson
SBSeyoun Byun
Seyoun Byun
DPDouglas Phanstiel
Douglas Phanstiel
Osteoarthritis (OA) poses a significant healthcare burden with limited treatment options. While genome-wide association studies (GWAS) have identified over 100 OA-associated loci, translating these findings into therapeutic targets remains challenging. Integrating expression quantitative trait loci (eQTL), 3D chromatin structure, and other genomic approaches with OA GWAS data offers a promising approach to elucidate disease mechanisms; however, comprehensive eQTL maps in OA-relevant tissues and conditions remain scarce. We mapped gene expression, chromatin accessibility, and 3D chromatin structure in primary human articular chondrocytes in both resting and OA-mimicking conditions. We identified thousands of differentially expressed genes, including those associated with differences in sex and age. RNA-seq in chondrocytes from 101 donors across two conditions uncovered 3782 unique eGenes, including 420 that exhibited strong and significant condition-specific effects. Colocalization with OA GWAS signals revealed 13 putative OA risk genes, 10 of which have not been previously identified. Chromatin accessibility and 3D chromatin structure provided insights into the mechanisms and conditional specificity of these variants. Our findings shed light on OA pathogenesis and highlight potential targets for therapeutic development. Highlights ∘ Comprehensive analysis of sex- and age-related global gene expression in human chondrocytes revealed differences that correlate with osteoarthritis ∘ First response eQTLs in chondrocytes treated with an OA-related stimulus ∘ Deeply sequenced Hi-C in resting and activated chondrocytes helps connect OA risk variants to their putative causal genes ∘ Colocalization analysis reveals 13 (including 10 novel) putative OA risk genes

20 April 2026 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
JDJorge Fernandez Davila
Jorge Fernandez Davila
RARalph A. Alberto
Ralph A. Alberto
SBSeyoun Byun
Seyoun Byun
SDSusan D’COsta
Susan D’COsta
JSJacqueline Shine
Jacqueline Shine
RLRichard F. Loeser
Richard F. Loeser
To investigate the effects of a matrikine, fibronectin fragment (FN7-10), on human osteoarthritic (OA) synovial fibroblasts and implications for inflammation and cartilage degradation. Joint tissue was obtained from 50 OA patients undergoing knee arthroplasty. Isolated synovial fibroblasts were treated with 1 µM of FN7-10 or PBS as control. Cytokine protein arrays were used to identify differentially secreted inflammatory mediators in conditioned media (CM). Bulk RNA-seq was used to evaluate transcriptional changes. Monocytic THP-1 cells in transwell assays were used to evaluate chemotactic activity of CM. Macrophage differentiation of THP-1 cells was assessed via qPCR and flow cytometry. Chondrocyte gene expression was evaluated by qPCR and glycosaminoglycan (GAG) production by Alcian blue assays. FN7-10 stimulation of synovial fibroblasts induced an inflammatory secretome, including production of chemokines. RNA-seq analysis confirmed FN7-10 induced upregulation of chemokines, including CCL5, CCL7, CCL8, CCL20, CXCL5 and CXCL10, which displayed mean transcriptional log-2-fold changes of 3.89 (CI, 2.81 - 4.97). CM from FN7-10-stimulated synovial fibroblasts increased THP-1 chemotaxis by 7.8-fold (CI, 3.26 - 12.35) which was reduced by CCR2 or CXCR2 inhibitors and promoted monocyte to macrophage differentiation characterized by an increase in pro-inflammatory gene expression and CD14. Chondrocytes treated with FN7-10 synovial fibroblast CM showed elevated IL6 and MMP1 and decreased ACAN and COL2A1 expression, along with reduced GAG levels. The matrikine FN7-10 promotes an inflammatory synovial fibroblast phenotype. Proinflammatory mediators, including chemokines, released from activated synovial fibroblasts recruit monocytes that may exacerbate joint inflammation and can also promote increased catabolic activity in chondrocytes.

22 May 2026 in bioRxiv
Verified
Preprint
Open access
SDSusan D’COsta
Susan D’COsta
SCShailesh K. Choudhary
Shailesh K. Choudhary
GKGrace E. Kenney
Grace E. Kenney
JSJacqueline Shine
Jacqueline Shine
BDBrian Diekman
Brian Diekman
DPDouglas Phanstiel
Douglas Phanstiel
Alpha-gal Syndrome (AGS) is a potentially life-threatening allergy caused by an IgE-mediated immune response to galactose-α-1,3-galactose (alpha-gal), a carbohydrate epitope present in most mammalian meats. Currently, strict avoidance of mammalian meat remains the primary management strategy for affected individuals, and alpha-gal-free beef is not commercially available. Here, we leverage cultivated meat as a biotechnology plat-form to address this unmet clinical need by engineering alpha-gal–free bovine muscle cells. Using CRISPR/Cas9 genome editing, we disrupted GGTA1, the gene encoding α1,3-galactosyltransferase, in immortalized bovine satellite cells (iBSCs). High-efficiency editing produced clonal GGTA1 knockout iBSCs harboring a homozygous frameshift mutation. Flow cytometry and immunofluorescence confirmed loss of the alpha-gal epitope, while bulk RNA-seq indicated minimal disruption of global gene expression and preserved myogenic differentiation capacity. Importantly, lysates from GGTA1 knockout iBSCs elicited substantially reduced basophil activation in assays using plasma from a patient with AGS, indicating reduced basophil activation consistent with reduced allergenic potential. Together, these findings establish a proof of concept for engineering AGS-compatible cultivated meat and demonstrate the potential of cultivated meat technologies to address human health challenges. HIGHLIGHTS: ∘ CRISPR/Cas9-mediated disruption of GGTA1 eliminated alpha-gal from bovine satellite cells ∘ GGTA1 knockout cells retained myogenic identity and differentiation capacity ∘ GGTA1 knockout reduced basophil activation in an alpha-gal syndrome immune assay ∘ Genome-edited bovine cells provide a proof of concept for AGS-compatible cultivated meat

9 August 2019 in bioRxiv
Verified
Preprint
Open access
SDSusan D’costa
Susan D’costa
MRMatthew J. Rich
Matthew J. Rich
BDBrian O. Diekman
Brian O. Diekman
Risk factors for the development of osteoarthritis (OA) include genetic background and focal cartilage injury. The search for disease-modifying OA therapies would benefit from a more comprehensive knowledge of the genetic variants that contribute to chondrocyte dysfunction and the barriers to cartilage regeneration. One goal of this study was to establish a system for producing engineered cartilage tissue from genetically-defined primary human chondrocytes through genome editing and single-cell expansion. This process was utilized to investigate the functional effect of bi-allelic knockout of the cell cycle inhibitor p21. The use of ribonucleoprotein (RNP) CRISPR/Cas9 complexes targeting two sites in the coding region of p21 resulted in a high frequency (16%) of colonies with homozygous p21 knockout. Chondrogenic pellet cultures from expanded chondrocytes with complete loss of p21 produced more glycosaminoglycans (GAG) and maintained a higher cell number. Single-cell derived colonies retained the potential for robust matrix production after expansion, allowing for analysis of colony variability from the same population of targeted cells. The effect of enhanced cartilage matrix production in p21 knockout chondrocytes persisted when matrix production from individual colonies was analyzed. Chondrocytes had lower levels of p21 protein with further expansion, and the difference in GAG production with p21 knockout was strongest at early passages. These results support previous findings that implicate p21 as a barrier to cartilage matrix production and regenerative capacity. Further, this work establishes the use of genome-edited human chondrocytes as a promising approach for engineered tissue models containing user-defined gene knockouts and other genetic variants for investigation of OA pathogenesis.